Schroder Investment Management Group Cuts Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Schroder Investment Management Group reduced its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,434 shares of the biotechnology company's stock after selling 57,865 shares during the period. Schroder Investment Management Group owned about 0.06% of Blueprint Medicines worth $3,337,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines in the third quarter worth approximately $108,000. Captrust Financial Advisors boosted its stake in shares of Blueprint Medicines by 3.4% in the third quarter. Captrust Financial Advisors now owns 17,904 shares of the biotechnology company's stock worth $1,656,000 after acquiring an additional 582 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Blueprint Medicines by 77.5% in the third quarter. Verition Fund Management LLC now owns 9,759 shares of the biotechnology company's stock worth $903,000 after acquiring an additional 4,260 shares during the last quarter. Quarry LP acquired a new stake in shares of Blueprint Medicines in the third quarter worth approximately $32,000. Finally, State Street Corp boosted its stake in shares of Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after acquiring an additional 385,818 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BPMC shares. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Wedbush reiterated an "outperform" rating and set a $128.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Morgan Stanley assumed coverage on Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective on the stock. Finally, Wolfe Research assumed coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They issued an "outperform" rating on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.

Remove Ads

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36. Following the completion of the sale, the chief operating officer now directly owns 67,109 shares of the company's stock, valued at $7,391,385.26. This represents a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 2,250 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the sale, the insider now directly owns 14,967 shares of the company's stock, valued at approximately $1,496,700. This represents a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,608 shares of company stock valued at $3,319,587. 4.21% of the stock is currently owned by corporate insiders.

Blueprint Medicines Stock Down 4.5 %

BPMC traded down $3.69 on Thursday, hitting $78.36. 123,326 shares of the company were exchanged, compared to its average volume of 753,433. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -72.55 and a beta of 0.75. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The firm has a 50-day moving average price of $92.19 and a two-hundred day moving average price of $93.62.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, equities analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.